Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas

Abstract Occurrence of resistance to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) approved in ovarian carcinoma, has already been shown in clinical settings. Identifying combination treatments to sensitize tumor cells and/or overcome resistance to olaparib is critical. Polo-like...

Full description

Bibliographic Details

Published in:	Cell Death and Disease
Main Authors:	Michela Chiappa, Alessandra Decio, Luca Guarrera, Ilaria Mengoli, Anju Karki, Divora Yemane, Carmen Ghilardi, Eugenio Scanziani, Simone Canesi, Maria C. Barbera, Ilaria Craparotta, Marco Bolis, Robert Fruscio, Chiara Grasselli, Tommaso Ceruti, Massimo Zucchetti, Jesse C. Patterson, Robin A. Lu, Micheal B. Yaffe, Maya Ridinger, Giovanna Damia, Federica Guffanti
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-07-01
Online Access:	https://doi.org/10.1038/s41419-024-06894-1